1
|
Vanlieshout TL, Stouth DW, Raziee R, Sraka ASJ, Masood HA, Ng SY, Mattina SR, Mikhail AI, Manta A, Ljubicic V. Sex-Specific Effect of CARM1 in Skeletal Muscle Adaptations to Exercise. Med Sci Sports Exerc 2024; 56:486-498. [PMID: 37882083 DOI: 10.1249/mss.0000000000003333] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2023]
Abstract
PURPOSE The purpose of this study was to determine how the intersection of coactivator-associated arginine methyltransferase 1 (CARM1) and biological sex affects skeletal muscle adaptations to chronic physical activity. METHODS Twelve-week-old female (F) and male (M) wild-type (WT) and CARM1 skeletal muscle-specific knockout (mKO) mice were randomly assigned to sedentary (SED) or voluntary wheel running (VWR) experimental groups. For 8 wk, the animals in the VWR cohort had volitional access to running wheels. Subsequently, we performed whole-body functional tests, and 48 h later muscles were harvested for molecular analysis. Western blotting, enzyme activity assays, as well as confocal and transmission electron microscopy were used to examine skeletal muscle biology. RESULTS Our data reveal a sex-dependent reduction in VWR volume caused by muscle-specific ablation of CARM1, as F CARM1 mKO mice performed less chronic, volitional exercise than their WT counterparts. Regardless of VWR output, exercise-induced adaptations in physiological function were similar between experimental groups. A broad panel of protein arginine methyltransferase (PRMT) biology measurements, including markers of arginine methyltransferase expression and activity, were unaffected by VWR, except for CARM1 and PRMT7 protein levels, which decreased and increased with VWR, respectively. Changes in myofiber morphology and mitochondrial protein content showed similar trends among animals. However, a closer examination of transmission electron microscopy images revealed contrasting responses to VWR in CARM1 mKO mice compared with WT littermates, particularly in mitochondrial size and fractional area. CONCLUSIONS The present findings demonstrate that CARM1 mKO reduces daily running volume in F mice, as well as exercise-evoked skeletal muscle mitochondrial plasticity, which indicates that this enzyme plays an essential role in sex-dependent differences in exercise performance and mitochondrial health.
Collapse
|
2
|
Epigenetic mechanisms in breast cancer therapy and resistance. Nat Commun 2021; 12:1786. [PMID: 33741974 PMCID: PMC7979820 DOI: 10.1038/s41467-021-22024-3] [Citation(s) in RCA: 188] [Impact Index Per Article: 62.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2020] [Accepted: 02/22/2021] [Indexed: 02/06/2023] Open
Abstract
The majority of breast cancers express the estrogen receptor (ERα) and agents targeting this pathway represent the main treatment modality. Endocrine therapy has proven successful in the treatment of hormone-responsive breast cancer since its early adoption in the 1940s as an ablative therapy. Unfortunately, therapeutic resistance arises, leading to disease recurrence and relapse. Recent studies increased our understanding in how changes to the chromatin landscape and deregulation of epigenetic factors orchestrate the resistant phenotype. Here, we will discuss how the epigenome is an integral determinant in hormone therapy response and why epigenetic factors are promising targets for overcoming clinical resistance. Endocrine therapy has been the mainstay for hormone responsive breast cancer treatment. Here, Garcia-Martinez and colleagues discuss epigenetic mechanisms regulating ER + breast cancer and endocrine therapy resistance, and highlight approaches to rewire the cancer epigenome to improve targeted therapies for this cancer.
Collapse
|
3
|
Cytoplasmic ERα and NFκB Promote Cell Survival in Mouse Mammary Cancer Cell Lines. Discov Oncol 2020; 11:76-86. [PMID: 32008217 DOI: 10.1007/s12672-020-00378-2] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/21/2019] [Accepted: 01/16/2020] [Indexed: 12/15/2022] Open
Abstract
There is a desperate need in the field for mouse mammary tumors and cell lines that faithfully mimic estrogen receptor (ER) expression and activity found in human breast cancers. We found that several mouse mammary cancer cell lines express ER but fail to demonstrate classical estrogen-driven proliferation or transcriptional activity. We investigated whether these cell lines may be used to model tamoxifen resistance by using small molecule inhibitors to signaling pathways known to contribute to resistance. We found that the combination of NFκB inhibition and ER antagonists significantly reduced cell proliferation in vitro, as well as growth of syngeneic tumors. Surprisingly, we found that ER was localized to the cytoplasm, regardless of any type of treatment. Based on this, we probed extra-nuclear functions of ER and found that co-inhibition of ER and NFκB led to an increase in oxidative stress and apoptosis. Together, these findings suggest that cytoplasmic ER and NFκB may play redundant roles in protecting mammary cancer cells from oxidative stress and cell death. Although this study has not identified a mouse model with classical ER activity, cytoplasmic ER has been described in a small subset of human breast tumors, suggesting that these findings may be relevant for some breast cancer patients.
Collapse
|
4
|
The Development of Tetrazole Derivatives as Protein Arginine Methyltransferase I (PRMT I) Inhibitors. Int J Mol Sci 2019; 20:ijms20153840. [PMID: 31390828 PMCID: PMC6695598 DOI: 10.3390/ijms20153840] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2019] [Revised: 08/01/2019] [Accepted: 08/01/2019] [Indexed: 02/07/2023] Open
Abstract
Protein arginine methyltransferase 1 (PRMT1) can catalyze protein arginine methylation by transferring the methyl group from S-adenosyl-L-methionine (SAM) to the guanidyl nitrogen atom of protein arginine, which influences a variety of biological processes. The dysregulation of PRMT1 is involved in a diverse range of diseases, including cancer. Therefore, there is an urgent need to develop novel and potent PRMT1 inhibitors. In the current manuscript, a series of 1-substituted 1H-tetrazole derivatives were designed and synthesized by targeting at the substrate arginine-binding site on PRMT1, and five compounds demonstrated significant inhibitory effects against PRMT1. The most potent PRMT1 inhibitor, compound 9a, displayed non-competitive pattern with respect to either SAM or substrate arginine, and showed the strong selectivity to PRMT1 compared to PRMT5, which belongs to the type II PRMT family. It was observed that the compound 9a inhibited the functions of PRMT1 and relative factors within this pathway, and down-regulated the canonical Wnt/β-catenin signaling pathway. The binding of compound 9a to PRMT1 was carefully analyzed by using molecular dynamic simulations and binding free energy calculations. These studies demonstrate that 9a was a potent PRMT1 inhibitor, which could be used as lead compound for further drug discovery.
Collapse
|
5
|
Wang SCM, Dowhan DH, Muscat GEO. Epigenetic arginine methylation in breast cancer: emerging therapeutic strategies. J Mol Endocrinol 2019; 62:R223-R237. [PMID: 30620710 DOI: 10.1530/jme-18-0224] [Citation(s) in RCA: 27] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/11/2018] [Accepted: 01/07/2019] [Indexed: 02/06/2023]
Abstract
Breast cancer is a heterogeneous disease, and the complexity of breast carcinogenesis is associated with epigenetic modification. There are several major classes of epigenetic enzymes that regulate chromatin activity. This review will focus on the nine mammalian protein arginine methyltransferases (PRMTs) and the dysregulation of PRMT expression and function in breast cancer. This class of enzymes catalyse the mono- and (symmetric and asymmetric) di-methylation of arginine residues on histone and non-histone target proteins. PRMT signalling (and R methylation) drives cellular proliferation, cell invasion and metastasis, targeting (i) nuclear hormone receptor signalling, (ii) tumour suppressors, (iii) TGF-β and EMT signalling and (iv) alternative splicing and DNA/chromatin stability, influencing the clinical and survival outcomes in breast cancer. Emerging reports suggest that PRMTs are also implicated in the development of drug/endocrine resistance providing another prospective avenue for the treatment of hormone resistance and associated metastasis. The complexity of PRMT signalling is further underscored by the degree of alternative splicing and the scope of variant isoforms (with distinct properties) within each PRMT family member. The evolution of PRMT inhibitors, and the ongoing clinical trials of PRMT inhibitors against a subgroup of solid cancers, coupled to the track record of lysine methyltransferases inhibitors in phase I/II clinical trials against cancer underscores the potential therapeutic utility of targeting PRMT epigenetic enzymes to improve survival outcomes in aggressive and metastatic breast cancer.
Collapse
Affiliation(s)
- Shu-Ching M Wang
- Cell Biology and Molecular Medicine Division, The University of Queensland, Institute for Molecular Bioscience, St Lucia, Australia
| | - Dennis H Dowhan
- Cell Biology and Molecular Medicine Division, The University of Queensland, Institute for Molecular Bioscience, St Lucia, Australia
| | - George E O Muscat
- Cell Biology and Molecular Medicine Division, The University of Queensland, Institute for Molecular Bioscience, St Lucia, Australia
| |
Collapse
|
6
|
Dysregulation of histone methyltransferases in breast cancer - Opportunities for new targeted therapies? Mol Oncol 2016; 10:1497-1515. [PMID: 27717710 DOI: 10.1016/j.molonc.2016.09.003] [Citation(s) in RCA: 51] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2016] [Revised: 09/14/2016] [Accepted: 09/14/2016] [Indexed: 01/24/2023] Open
Abstract
Histone methyltransferases (HMTs) catalyze the methylation of lysine and arginine residues on histone tails and non-histone targets. These important post-translational modifications are exquisitely regulated and affect chromatin compaction and transcriptional programs leading to diverse biological outcomes. There is accumulating evidence that genetic alterations of several HMTs impinge on oncogenic or tumor-suppressor functions and influence both cancer initiation and progression. HMTs therefore represent an opportunity for therapeutic targeting in those patients with tumors in which HMTs are dysregulated, to reverse the histone marks and transcriptional programs associated with aggressive tumor behavior. In this review, we describe the known histone methyltransferases and their emerging roles in breast cancer tumorigenesis.
Collapse
|
7
|
Hu H, Qian K, Ho MC, Zheng YG. Small Molecule Inhibitors of Protein Arginine Methyltransferases. Expert Opin Investig Drugs 2016; 25:335-58. [PMID: 26789238 DOI: 10.1517/13543784.2016.1144747] [Citation(s) in RCA: 92] [Impact Index Per Article: 11.5] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
INTRODUCTION Arginine methylation is an abundant posttranslational modification occurring in mammalian cells and catalyzed by protein arginine methyltransferases (PRMTs). Misregulation and aberrant expression of PRMTs are associated with various disease states, notably cancer. PRMTs are prominent therapeutic targets in drug discovery. AREAS COVERED The authors provide an updated review of the research on the development of chemical modulators for PRMTs. Great efforts are seen in screening and designing potent and selective PRMT inhibitors, and a number of micromolar and submicromolar inhibitors have been obtained for key PRMT enzymes such as PRMT1, CARM1, and PRMT5. The authors provide a focus on their chemical structures, mechanism of action, and pharmacological activities. Pros and cons of each type of inhibitors are also discussed. EXPERT OPINION Several key challenging issues exist in PRMT inhibitor discovery. Structural mechanisms of many PRMT inhibitors remain unclear. There lacks consistency in potency data due to divergence of assay methods and conditions. Physiologically relevant cellular assays are warranted. Substantial engagements are needed to investigate pharmacodynamics and pharmacokinetics of the new PRMT inhibitors in pertinent disease models. Discovery and evaluation of potent, isoform-selective, cell-permeable and in vivo-active PRMT modulators will continue to be an active arena of research in years ahead.
Collapse
Affiliation(s)
- Hao Hu
- a Department of Pharmaceutical and Biomedical Sciences , The University of Georgia , Athens , GA , USA
| | - Kun Qian
- a Department of Pharmaceutical and Biomedical Sciences , The University of Georgia , Athens , GA , USA
| | - Meng-Chiao Ho
- b Institute of Biological Chemistry , Academia Sinica , Nankang , Taipei , Taiwan
| | - Y George Zheng
- a Department of Pharmaceutical and Biomedical Sciences , The University of Georgia , Athens , GA , USA
| |
Collapse
|
8
|
Lee KH, Tsai WJ, Chen YW, Yang WC, Lee CY, Ou SM, Chen YT, Chien CC, Lee PC, Chung MY, Lin CC. Genotype polymorphisms of genes regulating nitric oxide synthesis determine long-term arteriovenous fistula patency in male hemodialysis patients. Ren Fail 2015; 38:228-37. [PMID: 26643995 DOI: 10.3109/0886022x.2015.1120096] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022] Open
Abstract
OBJECTIVES Nitric oxide (NO) is a pivotal vasoactive substance modulating arteriovenous fistula (AVF) patency for hemodialysis (HD). Since genetic background could be the predicting factor of AVF malfunction, we aimed to investigate whether the NO-related genotype polymorphisms determine AVF survival rates. METHODS This is a retrospective, observational, multi-center study involving eight HD units in Taiwan, enrolled 580 patients initiating maintenance HD via AVFs. Genotype polymorphisms of NO-biosynthesis regulating enzymes (DDAH-1, DDAH-2, eNOS and PRMT1) were compared between HD patients with (n = 161) and without (n = 419) history of AVF malfunction. Subgroup analyses by gender were performed to evaluate the genetic effect in difference sexes. RESULTS In overall population, statistically significant associations were not found between AVF malfunction and the genetic polymorphisms. In the male subgroup (n = 313), a single nucleotide polymorphism (SNP) of PRMT1, rs10415880 (IVS9-193 A/G), showed a significant association with AVF malfunction. Male patients with AA/AG genotype had inferior AVF outcomes compared to GG genotype, regarding primary patency (70.6% vs. 40.9%, p = 0.001), assisted primary patency (81.0% vs. 58.4%, p < 0.001) and secondary patency (83.7% vs. 63.3%, p < 0.001) at a 5-year observation period. From multivariate Cox regression model, the AA/AG genotypes of PRMT1 were an independent risk factor for AVF malfunction in men (HR: 4.539, 95% CI 2.015-10.223; p < 0.001). However, such associations were not found in women. CONCLUSIONS rs10415880, the SNP of PRMT1 could be a novel genetic marker associated with AVF malfunction risk in male HD patients. Those with AA and AG genotypes of rs10415880 may predict a poorer long-term patency of AVF.
Collapse
Affiliation(s)
- Kuo-Hua Lee
- a School of Medicine, National Yang-Ming University , Taipei , Taiwan ;,b Department of Medicine , Taipei Veterans General Hospital , Taipei , Taiwan ;,c Division of Nephrology , Taipei Veterans General Hospital , Taipei , Taiwan
| | - Wen-Jung Tsai
- d Institute of Genome Sciences, National Yang-Ming University , Taipei , Taiwan ;,e Department of Medical Research , Taipei Veterans General Hospital , Taipei , Taiwan
| | - Yu-Wei Chen
- a School of Medicine, National Yang-Ming University , Taipei , Taiwan ;,b Department of Medicine , Taipei Veterans General Hospital , Taipei , Taiwan ;,c Division of Nephrology , Taipei Veterans General Hospital , Taipei , Taiwan
| | - Wu-Chang Yang
- a School of Medicine, National Yang-Ming University , Taipei , Taiwan ;,b Department of Medicine , Taipei Veterans General Hospital , Taipei , Taiwan ;,c Division of Nephrology , Taipei Veterans General Hospital , Taipei , Taiwan
| | - Chiu-Yang Lee
- a School of Medicine, National Yang-Ming University , Taipei , Taiwan ;,f Division of Cardiovascular Surgery, Department of Surgery , Taipei Veterans General Hospital , Taipei , Taiwan
| | - Shuo-Ming Ou
- a School of Medicine, National Yang-Ming University , Taipei , Taiwan ;,b Department of Medicine , Taipei Veterans General Hospital , Taipei , Taiwan ;,c Division of Nephrology , Taipei Veterans General Hospital , Taipei , Taiwan
| | - Yung-Tai Chen
- a School of Medicine, National Yang-Ming University , Taipei , Taiwan ;,g Division of Nephrology, Department of Medicine , Taipei City Hospital-Heping Branch , Taipei , Taiwan
| | - Chih-Chiang Chien
- h Department of Nephrology , Chi-Mei Medical Center , Tainan , Taiwan ;,i Department of Medical Research , Chi-Mei Medical Center , Tainan , Taiwan ;,j Department of Food Nutrition , Chung Hwa University of Medical Technology , Tainan , Taiwan
| | - Pui-Ching Lee
- b Department of Medicine , Taipei Veterans General Hospital , Taipei , Taiwan
| | - Ming-Yi Chung
- d Institute of Genome Sciences, National Yang-Ming University , Taipei , Taiwan ;,e Department of Medical Research , Taipei Veterans General Hospital , Taipei , Taiwan
| | - Chih-Ching Lin
- a School of Medicine, National Yang-Ming University , Taipei , Taiwan ;,b Department of Medicine , Taipei Veterans General Hospital , Taipei , Taiwan ;,c Division of Nephrology , Taipei Veterans General Hospital , Taipei , Taiwan
| |
Collapse
|
9
|
Yu XR, Tang Y, Wang WJ, Ji S, Ma S, Zhong L, Zhang CH, Yang J, Wu XA, Fu ZY, Li LL, Yang SY. Discovery and structure–activity analysis of 4-((5-nitropyrimidin-4-yl)amino)benzimidamide derivatives as novel protein arginine methyltransferase 1 (PRMT1) inhibitors. Bioorg Med Chem Lett 2015; 25:5449-53. [DOI: 10.1016/j.bmcl.2015.06.095] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2015] [Revised: 06/10/2015] [Accepted: 06/25/2015] [Indexed: 01/04/2023]
|
10
|
Alam H, Gu B, Lee MG. Histone methylation modifiers in cellular signaling pathways. Cell Mol Life Sci 2015; 72:4577-92. [PMID: 26305020 DOI: 10.1007/s00018-015-2023-y] [Citation(s) in RCA: 80] [Impact Index Per Article: 8.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2015] [Revised: 08/02/2015] [Accepted: 08/14/2015] [Indexed: 02/06/2023]
Abstract
Histone methyltransferases and demethylases epigenetically regulate gene expression by modifying histone methylation status in numerous cellular processes, including cell differentiation and proliferation. These modifiers also control methylation levels of various non-histone proteins, such as effector proteins that play critical roles in cellular signaling networks. Dysregulated histone methylation modifiers alter expression of oncogenes and tumor suppressor genes and change methylation states of effector proteins, frequently resulting in aberrant cellular signaling cascades and cellular transformation. In this review, we summarize the role of histone methylation modifiers in regulating the following signaling pathways: NF-κB, RAS/RAF/MEK/MAPK, PI3K/Akt, Wnt/β-catenin, p53, and ERα.
Collapse
Affiliation(s)
- Hunain Alam
- Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX, 77030, USA
| | - Bingnan Gu
- Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX, 77030, USA
| | - Min Gyu Lee
- Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX, 77030, USA.
- Cancer Biology Program, Graduate School of Biomedical Sciences, The University of Texas Health Science Center, Houston, TX, 77030, USA.
- Center for Cancer Epigenetics, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
| |
Collapse
|
11
|
Pourié G, Martin N, Bossenmeyer-Pourié C, Akchiche N, Guéant-Rodriguez RM, Geoffroy A, Jeannesson E, El Hajj Chehadeh S, Mimoun K, Brachet P, Koziel V, Alberto JM, Helle D, Debard R, Leininger B, Daval JL, Guéant JL. Folate- and vitamin B12-deficient diet during gestation and lactation alters cerebellar synapsin expression via impaired influence of estrogen nuclear receptor α. FASEB J 2015; 29:3713-25. [PMID: 26018677 DOI: 10.1096/fj.14-264267] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2014] [Accepted: 05/11/2015] [Indexed: 02/06/2023]
Abstract
Deficiency in the methyl donors vitamin B12 and folate during pregnancy and postnatal life impairs proper brain development. We studied the consequences of this combined deficiency on cerebellum plasticity in offspring from rat mothers subjected to deficient diet during gestation and lactation and in rat neuroprogenitor cells expressing cerebellum markers. The major proteomic change in cerebellum of 21-d-old deprived females was a 2.2-fold lower expression of synapsins, which was confirmed in neuroprogenitors cultivated in the deficient condition. A pathway analysis suggested that these proteomic changes were related to estrogen receptor α (ER-α)/Src tyrosine kinase. The influence of impaired ER-α pathway was confirmed by abnormal negative geotaxis test at d 19-20 and decreased phsophorylation of synapsins in deprived females treated by ER-α antagonist 1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride (MPP). This effect was consistent with 2-fold decreased expression and methylation of ER-α and subsequent decreased ER-α/PPAR-γ coactivator 1 α (PGC-1α) interaction in deficiency condition. The impaired ER-α pathway led to decreased expression of synapsins through 2-fold decreased EGR-1/Zif-268 transcription factor and to 1.7-fold reduced Src-dependent phosphorylation of synapsins. The treatment of neuroprogenitors with either MPP or PP1 (4-(4'-phenoxyanilino)-6,7-dimethoxyquinazoline, 6,7-dimethoxy-N-(4-phenoxyphenyl)-4-quinazolinamine, SKI-1, Src-l1) Src inhibitor produced similar effects. In conclusion, the deficiency during pregnancy and lactation impairs the expression of synapsins through a deregulation of ER-α pathway.
Collapse
Affiliation(s)
- Grégory Pourié
- *Institut National de la Santé et de la Recherche Médicale, Unité 954, Nutrition-Genetics and Environmental Exposure, Medical Faculty and University Hospital Center, Nancy University, Vandoeuvre lès Nancy, France; Human Nutrition Unit, Unité Mixte de Recherche 1019 Institut National de la Recherche Agronomique/University of Auvergne, Institut National de la Recherche Agronomique Centre of Theix, Saint-Genès Champanelle, France; and Istituto di Ricovero e Cura a Carattere Scientifico, Oasi Maria Santissima-Institute for Research on Mental Retardation and Brain Aging, Troina, Italy
| | - Nicolas Martin
- *Institut National de la Santé et de la Recherche Médicale, Unité 954, Nutrition-Genetics and Environmental Exposure, Medical Faculty and University Hospital Center, Nancy University, Vandoeuvre lès Nancy, France; Human Nutrition Unit, Unité Mixte de Recherche 1019 Institut National de la Recherche Agronomique/University of Auvergne, Institut National de la Recherche Agronomique Centre of Theix, Saint-Genès Champanelle, France; and Istituto di Ricovero e Cura a Carattere Scientifico, Oasi Maria Santissima-Institute for Research on Mental Retardation and Brain Aging, Troina, Italy
| | - Carine Bossenmeyer-Pourié
- *Institut National de la Santé et de la Recherche Médicale, Unité 954, Nutrition-Genetics and Environmental Exposure, Medical Faculty and University Hospital Center, Nancy University, Vandoeuvre lès Nancy, France; Human Nutrition Unit, Unité Mixte de Recherche 1019 Institut National de la Recherche Agronomique/University of Auvergne, Institut National de la Recherche Agronomique Centre of Theix, Saint-Genès Champanelle, France; and Istituto di Ricovero e Cura a Carattere Scientifico, Oasi Maria Santissima-Institute for Research on Mental Retardation and Brain Aging, Troina, Italy
| | - Nassila Akchiche
- *Institut National de la Santé et de la Recherche Médicale, Unité 954, Nutrition-Genetics and Environmental Exposure, Medical Faculty and University Hospital Center, Nancy University, Vandoeuvre lès Nancy, France; Human Nutrition Unit, Unité Mixte de Recherche 1019 Institut National de la Recherche Agronomique/University of Auvergne, Institut National de la Recherche Agronomique Centre of Theix, Saint-Genès Champanelle, France; and Istituto di Ricovero e Cura a Carattere Scientifico, Oasi Maria Santissima-Institute for Research on Mental Retardation and Brain Aging, Troina, Italy
| | - Rosa Maria Guéant-Rodriguez
- *Institut National de la Santé et de la Recherche Médicale, Unité 954, Nutrition-Genetics and Environmental Exposure, Medical Faculty and University Hospital Center, Nancy University, Vandoeuvre lès Nancy, France; Human Nutrition Unit, Unité Mixte de Recherche 1019 Institut National de la Recherche Agronomique/University of Auvergne, Institut National de la Recherche Agronomique Centre of Theix, Saint-Genès Champanelle, France; and Istituto di Ricovero e Cura a Carattere Scientifico, Oasi Maria Santissima-Institute for Research on Mental Retardation and Brain Aging, Troina, Italy
| | - Andréa Geoffroy
- *Institut National de la Santé et de la Recherche Médicale, Unité 954, Nutrition-Genetics and Environmental Exposure, Medical Faculty and University Hospital Center, Nancy University, Vandoeuvre lès Nancy, France; Human Nutrition Unit, Unité Mixte de Recherche 1019 Institut National de la Recherche Agronomique/University of Auvergne, Institut National de la Recherche Agronomique Centre of Theix, Saint-Genès Champanelle, France; and Istituto di Ricovero e Cura a Carattere Scientifico, Oasi Maria Santissima-Institute for Research on Mental Retardation and Brain Aging, Troina, Italy
| | - Elise Jeannesson
- *Institut National de la Santé et de la Recherche Médicale, Unité 954, Nutrition-Genetics and Environmental Exposure, Medical Faculty and University Hospital Center, Nancy University, Vandoeuvre lès Nancy, France; Human Nutrition Unit, Unité Mixte de Recherche 1019 Institut National de la Recherche Agronomique/University of Auvergne, Institut National de la Recherche Agronomique Centre of Theix, Saint-Genès Champanelle, France; and Istituto di Ricovero e Cura a Carattere Scientifico, Oasi Maria Santissima-Institute for Research on Mental Retardation and Brain Aging, Troina, Italy
| | - Sarah El Hajj Chehadeh
- *Institut National de la Santé et de la Recherche Médicale, Unité 954, Nutrition-Genetics and Environmental Exposure, Medical Faculty and University Hospital Center, Nancy University, Vandoeuvre lès Nancy, France; Human Nutrition Unit, Unité Mixte de Recherche 1019 Institut National de la Recherche Agronomique/University of Auvergne, Institut National de la Recherche Agronomique Centre of Theix, Saint-Genès Champanelle, France; and Istituto di Ricovero e Cura a Carattere Scientifico, Oasi Maria Santissima-Institute for Research on Mental Retardation and Brain Aging, Troina, Italy
| | - Khalid Mimoun
- *Institut National de la Santé et de la Recherche Médicale, Unité 954, Nutrition-Genetics and Environmental Exposure, Medical Faculty and University Hospital Center, Nancy University, Vandoeuvre lès Nancy, France; Human Nutrition Unit, Unité Mixte de Recherche 1019 Institut National de la Recherche Agronomique/University of Auvergne, Institut National de la Recherche Agronomique Centre of Theix, Saint-Genès Champanelle, France; and Istituto di Ricovero e Cura a Carattere Scientifico, Oasi Maria Santissima-Institute for Research on Mental Retardation and Brain Aging, Troina, Italy
| | - Patrick Brachet
- *Institut National de la Santé et de la Recherche Médicale, Unité 954, Nutrition-Genetics and Environmental Exposure, Medical Faculty and University Hospital Center, Nancy University, Vandoeuvre lès Nancy, France; Human Nutrition Unit, Unité Mixte de Recherche 1019 Institut National de la Recherche Agronomique/University of Auvergne, Institut National de la Recherche Agronomique Centre of Theix, Saint-Genès Champanelle, France; and Istituto di Ricovero e Cura a Carattere Scientifico, Oasi Maria Santissima-Institute for Research on Mental Retardation and Brain Aging, Troina, Italy
| | - Violette Koziel
- *Institut National de la Santé et de la Recherche Médicale, Unité 954, Nutrition-Genetics and Environmental Exposure, Medical Faculty and University Hospital Center, Nancy University, Vandoeuvre lès Nancy, France; Human Nutrition Unit, Unité Mixte de Recherche 1019 Institut National de la Recherche Agronomique/University of Auvergne, Institut National de la Recherche Agronomique Centre of Theix, Saint-Genès Champanelle, France; and Istituto di Ricovero e Cura a Carattere Scientifico, Oasi Maria Santissima-Institute for Research on Mental Retardation and Brain Aging, Troina, Italy
| | - Jean-Marc Alberto
- *Institut National de la Santé et de la Recherche Médicale, Unité 954, Nutrition-Genetics and Environmental Exposure, Medical Faculty and University Hospital Center, Nancy University, Vandoeuvre lès Nancy, France; Human Nutrition Unit, Unité Mixte de Recherche 1019 Institut National de la Recherche Agronomique/University of Auvergne, Institut National de la Recherche Agronomique Centre of Theix, Saint-Genès Champanelle, France; and Istituto di Ricovero e Cura a Carattere Scientifico, Oasi Maria Santissima-Institute for Research on Mental Retardation and Brain Aging, Troina, Italy
| | - Deborah Helle
- *Institut National de la Santé et de la Recherche Médicale, Unité 954, Nutrition-Genetics and Environmental Exposure, Medical Faculty and University Hospital Center, Nancy University, Vandoeuvre lès Nancy, France; Human Nutrition Unit, Unité Mixte de Recherche 1019 Institut National de la Recherche Agronomique/University of Auvergne, Institut National de la Recherche Agronomique Centre of Theix, Saint-Genès Champanelle, France; and Istituto di Ricovero e Cura a Carattere Scientifico, Oasi Maria Santissima-Institute for Research on Mental Retardation and Brain Aging, Troina, Italy
| | - Renée Debard
- *Institut National de la Santé et de la Recherche Médicale, Unité 954, Nutrition-Genetics and Environmental Exposure, Medical Faculty and University Hospital Center, Nancy University, Vandoeuvre lès Nancy, France; Human Nutrition Unit, Unité Mixte de Recherche 1019 Institut National de la Recherche Agronomique/University of Auvergne, Institut National de la Recherche Agronomique Centre of Theix, Saint-Genès Champanelle, France; and Istituto di Ricovero e Cura a Carattere Scientifico, Oasi Maria Santissima-Institute for Research on Mental Retardation and Brain Aging, Troina, Italy
| | - Brigitte Leininger
- *Institut National de la Santé et de la Recherche Médicale, Unité 954, Nutrition-Genetics and Environmental Exposure, Medical Faculty and University Hospital Center, Nancy University, Vandoeuvre lès Nancy, France; Human Nutrition Unit, Unité Mixte de Recherche 1019 Institut National de la Recherche Agronomique/University of Auvergne, Institut National de la Recherche Agronomique Centre of Theix, Saint-Genès Champanelle, France; and Istituto di Ricovero e Cura a Carattere Scientifico, Oasi Maria Santissima-Institute for Research on Mental Retardation and Brain Aging, Troina, Italy
| | - Jean-Luc Daval
- *Institut National de la Santé et de la Recherche Médicale, Unité 954, Nutrition-Genetics and Environmental Exposure, Medical Faculty and University Hospital Center, Nancy University, Vandoeuvre lès Nancy, France; Human Nutrition Unit, Unité Mixte de Recherche 1019 Institut National de la Recherche Agronomique/University of Auvergne, Institut National de la Recherche Agronomique Centre of Theix, Saint-Genès Champanelle, France; and Istituto di Ricovero e Cura a Carattere Scientifico, Oasi Maria Santissima-Institute for Research on Mental Retardation and Brain Aging, Troina, Italy
| | - Jean-Louis Guéant
- *Institut National de la Santé et de la Recherche Médicale, Unité 954, Nutrition-Genetics and Environmental Exposure, Medical Faculty and University Hospital Center, Nancy University, Vandoeuvre lès Nancy, France; Human Nutrition Unit, Unité Mixte de Recherche 1019 Institut National de la Recherche Agronomique/University of Auvergne, Institut National de la Recherche Agronomique Centre of Theix, Saint-Genès Champanelle, France; and Istituto di Ricovero e Cura a Carattere Scientifico, Oasi Maria Santissima-Institute for Research on Mental Retardation and Brain Aging, Troina, Italy
| |
Collapse
|
12
|
Shi SP, Xu HD, Wen PP, Qiu JD. Progress and challenges in predicting protein methylation sites. MOLECULAR BIOSYSTEMS 2015; 11:2610-9. [DOI: 10.1039/c5mb00259a] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
We review the progress in the prediction of protein methylation sites in the past 10 years and discuss the challenges that are faced while developing novel predictors in the future.
Collapse
Affiliation(s)
- Shao-Ping Shi
- Department of Chemistry
- Nanchang University
- Nanchang
- China
- Department of Mathematics
| | - Hao-Dong Xu
- Department of Chemistry
- Nanchang University
- Nanchang
- China
| | - Ping-Ping Wen
- Department of Chemistry
- Nanchang University
- Nanchang
- China
| | - Jian-Ding Qiu
- Department of Chemistry
- Nanchang University
- Nanchang
- China
| |
Collapse
|
13
|
Proteomic analysis of protein methylation in the yeast Saccharomyces cerevisiae. J Proteomics 2015; 114:226-33. [DOI: 10.1016/j.jprot.2014.07.032] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2014] [Revised: 07/09/2014] [Accepted: 07/20/2014] [Indexed: 11/23/2022]
|
14
|
Abstract
Mounting evidence suggests that protein methyltransferases (PMTs), which catalyze methylation of histone and nonhistone proteins, play a crucial role in diverse biological processes and human diseases. In particular, PMTs have been recognized as major players in regulating gene expression and chromatin state. PMTs are divided into two categories: protein lysine methyltransferases (PKMTs) and protein arginine methyltransferases (PRMTs). There has been a steadily growing interest in these enzymes as potential therapeutic targets and therefore discovery of PMT inhibitors has also been pursued increasingly over the past decade. Here, we present a perspective on selective, small-molecule inhibitors of PMTs with an emphasis on their discovery, characterization, and applicability as chemical tools for deciphering the target PMTs' physiological functions and involvement in human diseases. We highlight the current state of PMT inhibitors and discuss future directions and opportunities for PMT inhibitor discovery.
Collapse
Affiliation(s)
- H Ümit Kaniskan
- Department of Structural and Chemical Biology, ‡Department of Oncological Sciences, §Department of Pharmacology and Systems Therapeutics, Icahn School of Medicine at Mount Sinai , 1425 Madison Avenue, New York, New York 10029, United States
| | | | | |
Collapse
|
15
|
Baldwin RM, Morettin A, Côté J. Role of PRMTs in cancer: Could minor isoforms be leaving a mark? World J Biol Chem 2014; 5:115-29. [PMID: 24921003 PMCID: PMC4050107 DOI: 10.4331/wjbc.v5.i2.115] [Citation(s) in RCA: 37] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/30/2013] [Revised: 03/05/2014] [Accepted: 04/17/2014] [Indexed: 02/05/2023] Open
Abstract
Protein arginine methyltransferases (PRMTs) catalyze the methylation of a variety of protein substrates, many of which have been linked to the development, progression and aggressiveness of different types of cancer. Moreover, aberrant expression of PRMTs has been observed in several cancer types. While the link between PRMTs and cancer is a relatively new area of interest, the functional implications documented thus far warrant further investigations into its therapeutic potential. However, the expression of these enzymes and the regulation of their activity in cancer are still significantly understudied. Currently there are nine main members of the PRMT family. Further, the existence of alternatively spliced isoforms for several of these family members provides an additional layer of complexity. Specifically, PRMT1, PRMT2, CARM1 and PRMT7 have been shown to have alternative isoforms and others may be currently unrealized. Our knowledge with respect to the relative expression and the specific functions of these isoforms is largely lacking and needs attention. Here we present a review of the current knowledge of the known alternative PRMT isoforms and provide a rationale for how they may impact on cancer and represent potentially useful targets for the development of novel therapeutic strategies.
Collapse
|
16
|
Abstract
The last one and half a decade witnessed an outstanding re-emergence of attention and remarkable progress in the field of protein methylation. In the present article, we describe the early discoveries in research and review the role protein methylation played in the biological function of the antiproliferative gene, BTG2/TIS21/PC3.
Collapse
Affiliation(s)
- Woon Ki Paik
- Professor Emeritus, Temple University School of Medicine, Philadelphia, PA, USA
| | - Sangduk Kim
- Professor Emeritus, Temple University School of Medicine, Philadelphia, PA, USA
| | - In Kyoung Lim
- Department of Biochemistry and Molecular Biology, Ajou University School of Medicine, Suwon, Korea
| |
Collapse
|
17
|
Epigenetics of estrogen receptor signaling: role in hormonal cancer progression and therapy. Cancers (Basel) 2013; 3:1691-707. [PMID: 21814622 PMCID: PMC3147309 DOI: 10.3390/cancers3021691] [Citation(s) in RCA: 65] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022] Open
Abstract
Estrogen receptor (ERα) signaling plays a key role in hormonal cancer progression. ERα is a ligand-dependent transcription factor that modulates gene transcription via recruitment to the target gene chromatin. Emerging evidence suggests that ERα signaling has the potential to contribute to epigenetic changes. Estrogen stimulation is shown to induce several histone modifications at the ERα target gene promoters including acetylation, phosphorylation and methylation via dynamic interactions with histone modifying enzymes. Deregulation of enzymes involved in the ERα-mediated epigenetic pathway could play a vital role in ERα driven neoplastic processes. Unlike genetic alterations, epigenetic changes are reversible, and hence offer novel therapeutic opportunities to reverse ERα driven epigenetic changes. In this review, we summarize current knowledge on mechanisms by which ERα signaling potentiates epigenetic changes in cancer cells via histone modifications.
Collapse
|
18
|
Nagata C, Wada K, Tsuji M, Hayashi M, Takeda N, Yasuda K. Plasma amino acid profiles are associated with biomarkers of breast cancer risk in premenopausal Japanese women. Cancer Causes Control 2013; 25:143-9. [PMID: 24186145 DOI: 10.1007/s10552-013-0316-8] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2013] [Accepted: 10/19/2013] [Indexed: 01/12/2023]
Abstract
OBJECTIVE Recently, profiles of plasma amino acids have been utilized to detect diseases including breast cancer. However, there is a possibility that the amino acid status may be associated with the risk of breast cancer. We investigated the relationship of plasma levels of amino acids with levels of sex hormones and insulin-like growth factor (IGF)-1, which are relevant to the etiology of premenopausal breast cancer, in normal premenopausal women. METHODS Participants were 350 Japanese women who had regular menstrual cycles less than 40-day long. Fasting plasma samples were assayed for estradiol, testosterone, dehydroepiandrosterone sulfate, sex-hormone-binding globulin (SHBG), and IGF-1. A total of 20 amino acids in plasma were quantified by liquid chromatography-mass spectrometry. Information on lifestyle and reproductive factors was obtained using a self-administered questionnaire. RESULTS The plasma arginine level was significantly inversely correlated with plasma levels of total and free estradiol and IGF-1 after adjusting for age, body mass index, and phase of the menstrual cycle. Plasma leucine and tyrosine levels were significantly positively correlated with the free testosterone level. The ratio of plasma asparagine to the total amino acids was significantly positively correlated with SHBG level. CONCLUSIONS Plasma levels of some specific amino acids, such as arginine, leucine, tyrosine, and asparagine, were associated with the levels of sex hormones, SHBG, or IGF-1 in premenopausal women. However, the present cross-sectional study cannot provide a cause-effect relation. The implication of amino acids in the etiology of breast cancer needs to be addressed in future studies.
Collapse
Affiliation(s)
- Chisato Nagata
- Department of Epidemiology and Preventive Medicine, Gifu University Graduate School of Medicine, Gifu, 501-1194, Japan,
| | | | | | | | | | | |
Collapse
|
19
|
Wang L, Charoensuksai P, Watson NJ, Wang X, Zhao Z, Coriano CG, Kerr LR, Xu W. CARM1 automethylation is controlled at the level of alternative splicing. Nucleic Acids Res 2013; 41:6870-80. [PMID: 23723242 PMCID: PMC3737532 DOI: 10.1093/nar/gkt415] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
Abstract
Co-activator-associated arginine methyltransferase 1 (CARM1) is subjected to multiple post-translational modifications. Our previous finding that automethylation of CARM1 is essential for regulation of transcription and pre-mRNA splicing prompted us to investigate how automethylation is regulated. Here, we report that automethylation is regulated by alternative splicing of CARM1 mRNA to remove exon 15, containing the automethylation site. Specifically, we find that two major alternative transcripts encoding full-length CARM1 (CARM1FL) and CARM1 with exon 15 deleted (CARM1ΔE15) exist in cells, and each transcript produces the expected protein. Further biochemical characterizations of the automethylation-defective mutant and CARM1ΔE15 reveal overlapping yet different properties. Interestingly, other arginine methylation substrates also have missing exons encompassing the site(s) of methylation, suggesting that protein arginine methylation level may, in general, be controlled by the alternative splicing mechanism. Finally, we observed differential distribution of CARM1FL and CARM1ΔE15 in epithelial and stromal cells in normal mouse mammary gland. Thus, alternative splicing not only serves as the determinant for CARM1 automethylation but also generates cell type-specific isoforms that might regulate normal ERα biology in the mammary gland.
Collapse
Affiliation(s)
- Lu Wang
- McArdle Laboratory for Cancer Research, University of Wisconsin School of Medicine and Public Health, 1400 University Avenue, Madison, WI 53706, USA
| | | | | | | | | | | | | | | |
Collapse
|
20
|
Huang BW, Ray PD, Iwasaki K, Tsuji Y. Transcriptional regulation of the human ferritin gene by coordinated regulation of Nrf2 and protein arginine methyltransferases PRMT1 and PRMT4. FASEB J 2013; 27:3763-74. [PMID: 23699174 DOI: 10.1096/fj.12-226043] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
Antioxidant genes such as ferritin are transcriptionally activated in oxidative stress via the antioxidant responsive element (ARE), to which nuclear factor-E2-related factor 2 (Nrf2) binds and activates transcription. Histone modification plays a cooperative and essential role in transcriptional regulation; however, its role in antioxidant gene transcription remains elusive. Arsenic exposure activated ferritin transcription via the ARE concomitant with increased methylation of histones H4Arg3 (H4R3) and H3Arg17 (H3R17). To test our hypothesis that histone H4R3 and H3R17 methylation regulates ferritin transcription, H4R3 and H3R17 protein arginine (R) methyltransferases 1 and 4 (PRMT1 and PRMT4) were investigated. Arsenic exposure of human HaCaT keratinocytes induced nuclear accumulation of PRMT1 and PRMT4, histone H4R3 and H3R17 methylation proximal to the ARE, but not to the non-ARE regions of ferritin genes. PRMT1 or PRMT4 knockdown did not block Nrf2 nuclear accumulation but inhibited Nrf2 binding to the AREs by ∼40% (P<0.05), thus diminishing ferritin transcription in HaCaT and human primary keratinocytes and fibroblasts, causing enhanced cellular susceptibility to arsenic toxicity as evidenced by 2-fold caspase 3 activation. Focused microarray further characterized several oxidative stress response genes are subject to PRMT1 or PRMT4 regulation. Collectively, PRMT1 and PRMT4 regulate the ARE and cellular antioxidant response to arsenic.
Collapse
Affiliation(s)
- Bo-Wen Huang
- Department of Environmental and Molecular Toxicology, North Carolina State University, Campus Box 7633, Raleigh, NC 27695, USA
| | | | | | | |
Collapse
|
21
|
Zeng H, Wu J, Bedford MT, Sbardella G, Hoffmann FM, Bi K, Xu W. A TR-FRET-based functional assay for screening activators of CARM1. Chembiochem 2013; 14:827-35. [PMID: 23585185 PMCID: PMC3828750 DOI: 10.1002/cbic.201300029] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2013] [Indexed: 11/07/2022]
Abstract
Epigenetics is an emerging field that demands selective cell-permeable chemical probes to perturb, especially in vivo, the activity of specific enzymes involved in modulating the epigenetic codes. Coactivator-associated arginine methyltransferase 1 (CARM1) is a coactivator of estrogen receptor α (ERα), the main target in human breast cancer. We previously showed that twofold overexpression of CARM1 in MCF7 breast cancer cells increased the expression of ERα-target genes involved in differentiation and reduced cell proliferation, thus leading to the hypothesis that activating CARM1 by chemical activators might be therapeutically effective in breast cancer. Selective, potent, cell-permeable CARM1 activators will be essential to test this hypothesis. Here we report the development of a cell-based, time-resolved (TR) FRET assay that uses poly(A) binding protein 1 (PABP1) methylation to monitor cellular activity of CARM1. The LanthaScreen TR-FRET assay uses MCF7 cells expressing GFP-PABP1 fusion protein through BacMam gene delivery system, methyl-PABP1 specific antibody, and terbium-labeled secondary antibody. This assay has been validated as reflecting the expression and/or activity of CARM1 and optimized for high throughput screening to identify CARM1 allosteric activators. This TR-FRET platform serves as a generic tool for functional screening of cell-permeable, chemical modulators of CARM1 for elucidation of its in vivo functions.
Collapse
Affiliation(s)
- Hao Zeng
- Graduate Program in Cellular and Molecular Biology, McArdle Laboratory for Cancer Research and Carbone Comprehensive Cancer Center, University of Wisconsin, 1400 University Ave, Madison, WI 53706, USA
| | | | | | | | | | | | | |
Collapse
|
22
|
Modulation of estrogen receptor alpha activity and expression during breast cancer progression. VITAMINS AND HORMONES 2013; 93:135-60. [PMID: 23810005 DOI: 10.1016/b978-0-12-416673-8.00004-6] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Seventy percent of breast tumors express the estrogen receptor (ER), which is generally considered to predict a better outcome relative to ER-negative tumors, as they often respond to antiestrogen therapies. During cancer progression, mammary tumors can escape from estrogen control, resulting in the acquisition of invasive properties and resistance to treatment. ER expression is a dynamic phenomenon and is finely regulated at numerous levels, including the gene, mRNA, and protein levels. As a consequence, many molecular mechanisms have been implicated in modulating ER activity and estrogen signaling in mammary cancer. In fact, one-third of ER-positive breast cancer cells do not respond to first-line endocrine therapies, and a large subset of relapsing tumors retain ER expression. Increased knowledge of these mechanisms has led to the development of better prognostic methods and targeted therapies for patients; however, additional research is still needed to improve patient survival. In this chapter, we focus on the signaling pathways leading to changes in or loss of ER activity in breast cancer progression.
Collapse
|
23
|
Theillet FX, Smet-Nocca C, Liokatis S, Thongwichian R, Kosten J, Yoon MK, Kriwacki RW, Landrieu I, Lippens G, Selenko P. Cell signaling, post-translational protein modifications and NMR spectroscopy. JOURNAL OF BIOMOLECULAR NMR 2012; 54:217-36. [PMID: 23011410 PMCID: PMC4939263 DOI: 10.1007/s10858-012-9674-x] [Citation(s) in RCA: 140] [Impact Index Per Article: 11.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/28/2012] [Accepted: 09/07/2012] [Indexed: 05/13/2023]
Abstract
Post-translationally modified proteins make up the majority of the proteome and establish, to a large part, the impressive level of functional diversity in higher, multi-cellular organisms. Most eukaryotic post-translational protein modifications (PTMs) denote reversible, covalent additions of small chemical entities such as phosphate-, acyl-, alkyl- and glycosyl-groups onto selected subsets of modifiable amino acids. In turn, these modifications induce highly specific changes in the chemical environments of individual protein residues, which are readily detected by high-resolution NMR spectroscopy. In the following, we provide a concise compendium of NMR characteristics of the main types of eukaryotic PTMs: serine, threonine, tyrosine and histidine phosphorylation, lysine acetylation, lysine and arginine methylation, and serine, threonine O-glycosylation. We further delineate the previously uncharacterized NMR properties of lysine propionylation, butyrylation, succinylation, malonylation and crotonylation, which, altogether, define an initial reference frame for comprehensive PTM studies by high-resolution NMR spectroscopy.
Collapse
Affiliation(s)
- Francois-Xavier Theillet
- Department of NMR-Supported Structural Biology, Leibniz Institute of Molecular Pharmacology (FMP Berlin), In-cell NMR Group, Robert-Roessle Strasse 10, 13125 Berlin, German
| | - Caroline Smet-Nocca
- CNRS UMR 8576, Universite Lille Nord de France, 59655 Villeneuve d’Ascq, France
| | - Stamatios Liokatis
- Department of NMR-Supported Structural Biology, Leibniz Institute of Molecular Pharmacology (FMP Berlin), In-cell NMR Group, Robert-Roessle Strasse 10, 13125 Berlin, German
| | - Rossukon Thongwichian
- Department of NMR-Supported Structural Biology, Leibniz Institute of Molecular Pharmacology (FMP Berlin), In-cell NMR Group, Robert-Roessle Strasse 10, 13125 Berlin, German
| | - Jonas Kosten
- Department of NMR-Supported Structural Biology, Leibniz Institute of Molecular Pharmacology (FMP Berlin), In-cell NMR Group, Robert-Roessle Strasse 10, 13125 Berlin, German
| | - Mi-Kyung Yoon
- Department of Structural Biology, St. Jude Children’s Research Hospital, Memphis, TN, USA
| | - Richard W. Kriwacki
- Department of Structural Biology, St. Jude Children’s Research Hospital, Memphis, TN, USA
| | - Isabelle Landrieu
- CNRS UMR 8576, Universite Lille Nord de France, 59655 Villeneuve d’Ascq, France
| | - Guy Lippens
- CNRS UMR 8576, Universite Lille Nord de France, 59655 Villeneuve d’Ascq, France
| | - Philipp Selenko
- Department of NMR-Supported Structural Biology, Leibniz Institute of Molecular Pharmacology (FMP Berlin), In-cell NMR Group, Robert-Roessle Strasse 10, 13125 Berlin, German
| |
Collapse
|
24
|
Shi SP, Qiu JD, Sun XY, Suo SB, Huang SY, Liang RP. A method to distinguish between lysine acetylation and lysine methylation from protein sequences. J Theor Biol 2012; 310:223-30. [DOI: 10.1016/j.jtbi.2012.06.030] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2012] [Revised: 05/21/2012] [Accepted: 06/25/2012] [Indexed: 01/21/2023]
|
25
|
Dowhan DH, Harrison MJ, Eriksson NA, Bailey P, Pearen MA, Fuller PJ, Funder JW, Simpson ER, Leedman PJ, Tilley WD, Brown MA, Clarke CL, Muscat GEO. Protein arginine methyltransferase 6-dependent gene expression and splicing: association with breast cancer outcomes. Endocr Relat Cancer 2012; 19:509-26. [PMID: 22673335 DOI: 10.1530/erc-12-0100] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
Protein arginine methyltransferase-6 (PRMT6) regulates steroid-dependent transcription and alternative splicing and is implicated in endocrine system development and function, cell death, cell cycle, gene expression and cancer. Despite its role in these processes, little is known about its function and cellular targets in breast cancer. To identify novel gene targets regulated by PRMT6 in breast cancer cells, we used a combination of small interfering RNA and exon-specific microarray profiling in vitro coupled to in vivo validation in normal breast and primary human breast tumours. This approach, which allows the examination of genome-wide changes in individual exon usage and total transcript levels, demonstrated that PRMT6 knockdown significantly affected i) the transcription of 159 genes and ii) alternate splicing of 449 genes. The PRMT6-dependent transcriptional and alternative splicing targets identified in vitro were validated in human breast tumours. Using the list of genes differentially expressed between normal and PRMT6 knockdown cells, we generated a PRMT6-dependent gene expression signature that provides an indication of PRMT6 dysfunction in breast cancer cells. Interrogation of several well-studied breast cancer microarray expression datasets with the PRMT6 gene expression signature demonstrated that PRMT6 dysfunction is associated with better overall relapse-free and distant metastasis-free survival in the oestrogen receptor (ER (ESR1)) breast cancer subgroup. These results suggest that dysregulation of PRMT6-dependent transcription and alternative splicing may be involved in breast cancer pathophysiology and the molecular consequences identifying a unique and informative biomarker profile.
Collapse
Affiliation(s)
- Dennis H Dowhan
- Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland 4072, Australia.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
26
|
PMeS: prediction of methylation sites based on enhanced feature encoding scheme. PLoS One 2012; 7:e38772. [PMID: 22719939 PMCID: PMC3376144 DOI: 10.1371/journal.pone.0038772] [Citation(s) in RCA: 57] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2011] [Accepted: 05/14/2012] [Indexed: 01/16/2023] Open
Abstract
Protein methylation is predominantly found on lysine and arginine residues, and carries many important biological functions, including gene regulation and signal transduction. Given their important involvement in gene expression, protein methylation and their regulatory enzymes are implicated in a variety of human disease states such as cancer, coronary heart disease and neurodegenerative disorders. Thus, identification of methylation sites can be very helpful for the drug designs of various related diseases. In this study, we developed a method called PMeS to improve the prediction of protein methylation sites based on an enhanced feature encoding scheme and support vector machine. The enhanced feature encoding scheme was composed of the sparse property coding, normalized van der Waals volume, position weight amino acid composition and accessible surface area. The PMeS achieved a promising performance with a sensitivity of 92.45%, a specificity of 93.18%, an accuracy of 92.82% and a Matthew’s correlation coefficient of 85.69% for arginine as well as a sensitivity of 84.38%, a specificity of 93.94%, an accuracy of 89.16% and a Matthew’s correlation coefficient of 78.68% for lysine in 10-fold cross validation. Compared with other existing methods, the PMeS provides better predictive performance and greater robustness. It can be anticipated that the PMeS might be useful to guide future experiments needed to identify potential methylation sites in proteins of interest. The online service is available at http://bioinfo.ncu.edu.cn/inquiries_PMeS.aspx.
Collapse
|
27
|
Cha B, Jho EH. Protein arginine methyltransferases (PRMTs) as therapeutic targets. Expert Opin Ther Targets 2012; 16:651-64. [PMID: 22621686 DOI: 10.1517/14728222.2012.688030] [Citation(s) in RCA: 43] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
INTRODUCTION Protein arginine methyltransferases (PRMTs) add one or two monomethyl groups to the guanidino nitrogen atoms of arginine residues, resulting in epigenetic modification of histones or changes of protein-protein interactions, which in turn leads to the regulation of a variety of biological functions, including transcriptional activation/repression, signal transduction, cell differentiation, and embryonic development. As dysregulation of PRMTs has been observed in diverse types of cancers and modulation of their levels affects cancer cell growth, these enzymes are considered to be potential therapeutic targets. AREAS COVERED In this review, we examined recent advances in our understanding of the regulatory mechanisms of PRMT activity and the biological roles of PRMTs in embryonic stem cell, Wnt/β-catenin signaling, and cancer development. EXPERT OPINION The roles of PRMTs have been fairly well established, but further studies are required to determine how PRMTs are regulated by cellular signaling pathways in vivo. Since the usage of adult stem cells is under intense scrutiny by society, identification of the roles of PRMTs in adult stem cells is expected in the near future. Although small molecules specific to PRMTs with high potency in vitro have been identified, development of small molecules that can regulate the activity of PRMTs in vivo is urgently required for therapeutic purposes.
Collapse
Affiliation(s)
- Boksik Cha
- The University of Seoul, Department of Life Science, 90 Jeonnong-dong, Dongdaemun-gu, Seoul, 130-743, Republic of Korea
| | | |
Collapse
|
28
|
Tissue-specific and age-dependent expression of protein arginine methyltransferases (PRMTs) in male rat tissues. Biogerontology 2012; 13:329-36. [DOI: 10.1007/s10522-012-9379-2] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2012] [Accepted: 03/15/2012] [Indexed: 10/28/2022]
|
29
|
Centrella M, McCarthy TL. Estrogen receptor dependent gene expression by osteoblasts - direct, indirect, circumspect, and speculative effects. Steroids 2012; 77:174-84. [PMID: 22093482 DOI: 10.1016/j.steroids.2011.10.016] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/29/2011] [Accepted: 10/31/2011] [Indexed: 12/15/2022]
Abstract
Hormone activated estrogen receptors (ERs) have long been appreciated as potent mediators of gene expression in female reproductive tissues. These highly targeted responses likely evolved from more elemental roles in lower organisms, in agreement with their widespread effects in the cardiovascular, immunological, central nervous, and skeletal tissue systems. Still, despite intense investigation, the multiple and often perplexing roles of ERs retain significant attention. In the skeleton, this in part derives from apparently opposing effects by ER agonists on bone growth versus bone remodeling, and in younger versus older individuals. The complexity associated with ER activation can also derive from their interactions with other hormone and growth factor systems, and their direct and indirect effects on gene expression. We propose that part of this complexity results from essential interactions between ERs and other transcription factors, each with their own biochemical and molecular intricacies. Solving some of the many questions that persist may help to achieve better, or better directed, use of agents that can drive ER activation in focused and possibly tissue restricted ways.
Collapse
Affiliation(s)
- Michael Centrella
- Department of Surgery, Yale University School of Medicine, 310 Cedar Street, New Haven, CT 06520-8041, United States.
| | | |
Collapse
|
30
|
Erce MA, Pang CNI, Hart-Smith G, Wilkins MR. The methylproteome and the intracellular methylation network. Proteomics 2012; 12:564-86. [DOI: 10.1002/pmic.201100397] [Citation(s) in RCA: 70] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2011] [Revised: 09/23/2011] [Accepted: 10/17/2011] [Indexed: 12/30/2022]
|
31
|
Shi SP, Qiu JD, Sun XY, Suo SB, Huang SY, Liang RP. PLMLA: prediction of lysine methylation and lysine acetylation by combining multiple features. MOLECULAR BIOSYSTEMS 2012; 8:1520-7. [DOI: 10.1039/c2mb05502c] [Citation(s) in RCA: 65] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
|
32
|
Role of estrogen receptor signaling in breast cancer metastasis. Int J Breast Cancer 2011; 2012:654698. [PMID: 22295247 PMCID: PMC3262597 DOI: 10.1155/2012/654698] [Citation(s) in RCA: 114] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2011] [Revised: 09/16/2011] [Accepted: 09/19/2011] [Indexed: 12/21/2022] Open
Abstract
Metastatic breast cancer is a life-threatening stage of cancer and is the leading cause of death in advanced breast cancer patients. Estrogen signaling and the estrogen receptor (ER) are implicated in breast cancer progression, and the majority of the human breast cancers start out as estrogen dependent. Accumulating evidence suggests that ER signaling is complex, involving coregulatory proteins and extranuclear actions. ER-coregualtory proteins are tightly regulated under normal conditions with miss expression primarily reported in cancer. Deregulation of ER coregualtors or ER extranuclear signaling has potential to promote metastasis in ER-positive breast cancer cells. This review summarizes the emerging role of ER signaling in promoting metastasis of breast cancer cells, discusses the molecular mechanisms by which ER signaling contributes to metastasis, and explores possible therapeutic targets to block ER-driven metastasis.
Collapse
|
33
|
Cheng Y, Frazier M, Lu F, Cao X, Redinbo MR. Crystal structure of the plant epigenetic protein arginine methyltransferase 10. J Mol Biol 2011; 414:106-22. [PMID: 21986201 PMCID: PMC3217299 DOI: 10.1016/j.jmb.2011.09.040] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2011] [Revised: 09/20/2011] [Accepted: 09/24/2011] [Indexed: 01/07/2023]
Abstract
Protein arginine methyltransferase 10 (PRMT10) is a type I arginine methyltransferase that is essential for regulating flowering time in Arabidopsis thaliana. We present a 2.6 Å resolution crystal structure of A. thaliana PRMT 10 (AtPRMT10) in complex with a reaction product, S-adenosylhomocysteine. The structure reveals a dimerization arm that is 12-20 residues longer than PRMT structures elucidated previously; as a result, the essential AtPRMT10 dimer exhibits a large central cavity and a distinctly accessible active site. We employ molecular dynamics to examine how dimerization facilitates AtPRMT10 motions necessary for activity, and we show that these motions are conserved in other PRMT enzymes. Finally, functional data reveal that the 10 N-terminal residues of AtPRMT10 influence substrate specificity, and that enzyme activity is dependent on substrate protein sequences distal from the methylation site. Taken together, these data provide insights into the molecular mechanism of AtPRMT10, as well as other members of the PRMT family of enzymes. They highlight differences between AtPRMT10 and other PRMTs but also indicate that motions are a conserved element of PRMT function.
Collapse
Affiliation(s)
- Yuan Cheng
- Department of Biochemistry & Biophysics, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA,Program in Molecular & Cellular Biophysics, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
| | - Monica Frazier
- Department of Biochemistry & Biophysics, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA,Program in Molecular & Cellular Biophysics, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
| | - Falong Lu
- State Key Laboratory of Plant Genomics and Center for Plant Gene Research, Institute of Genetics and Developmental Biology, Chinese Academy of Sciences, Beijing, 100101, China,Graduate School, Chinese Academy of Sciences, Beijing, 100039, China
| | - Xiaofeng Cao
- State Key Laboratory of Plant Genomics and Center for Plant Gene Research, Institute of Genetics and Developmental Biology, Chinese Academy of Sciences, Beijing, 100101, China
| | - Matthew R. Redinbo
- Department of Biochemistry & Biophysics, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA,Program in Molecular & Cellular Biophysics, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA,Department of Chemistry, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA,Department of Microbiology & Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA,Correspondence: Matthew R. Redinbo, Ph.D., Department of Chemistry, Campus Box 3290, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599. Tel.:919-843-8910, Fax: 919-962-2388,
| |
Collapse
|
34
|
Maggi A. Liganded and unliganded activation of estrogen receptor and hormone replacement therapies. Biochim Biophys Acta Mol Basis Dis 2011; 1812:1054-60. [PMID: 21605666 DOI: 10.1016/j.bbadis.2011.05.001] [Citation(s) in RCA: 53] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2011] [Revised: 04/29/2011] [Accepted: 05/01/2011] [Indexed: 12/13/2022]
Abstract
Over the past two decades, our understanding of estrogen receptor physiology in mammals widened considerably as we acquired a deeper appreciation of the roles of estrogen receptor alpha and beta (ERα and ERβ) in reproduction as well as in bone and metabolic homeostasis, depression, vascular disorders, neurodegenerative diseases and cancer. In addition, our insights on ER transcriptional functions in cells increased considerably with the demonstration that ER activity is not strictly dependent on ligand availability. Indeed, unliganded ERs may be transcriptionally active and post-translational modifications play a major role in this context. The finding that several intracellular transduction molecules may regulate ER transcriptional programs indicates that ERs may act as a hub where several molecular pathways converge: this allows to maintain ER transcriptional activity in tune with all cell functions. Likely, the biological relevant role of ER was favored by evolution as a mean of integration between reproductive and metabolic functions. We here review the post-translational modifications modulating ER transcriptional activity in the presence or in the absence of estrogens and underline their potential role for ER tissue-specific activities. In our opinion, a better comprehension of the variety of molecular events that control ER activity in reproductive and non-reproductive organs is the foundation for the design of safer and more efficacious hormone-based therapies, particularly for menopause. This article is part of a Special Issue entitled: Translating Nuclear receptors from health to disease.
Collapse
Affiliation(s)
- Adriana Maggi
- Center of Excellence on Neurodegenerative Diseases and Department of Pharmacological Sciences, University of Milan, Milan, Italy.
| |
Collapse
|
35
|
Qiu QA, Lv YF, Chen YM, Lin YG, Wu HY, Liu N. Transfection of methylated oligonucleotides inactivates the CHFR gene in human colon cancer cell line SW480. Shijie Huaren Xiaohua Zazhi 2010; 18:3565-3568. [DOI: 10.11569/wcjd.v18.i33.3565] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
AIM: To investigate whether transfection of methylated oligonucleotides that are complementary to the CHFR (checkpoint with forkhead and ring finger domains) gene promoter inactivates the CHFR gene in human colon cancer cell line SW480 and to analyze the effect of CHFR inactivation on the biological behavior of SW480 cells.
METHODS: After methylated oligonucleotides that are complementary to the CHFR gene promoter were transfected into SW480 cells, MSP and RT-PCR were employed to detect the promoter methylation status and mRNA expression of the CHFR gene, respectively. MTT assay was used to detect the proliferation of SW480 cells before and after transfection.
RESULTS: In control SW480 cells, the promoter region of the CHFR gene was unmethylated and CHFR mRNA expression could be detected. After transfection of methylated oligonucleotides, CHFR gene promoter methylation was induced and CHFR mRNA expression was suppressed. The proliferation of SW480 cells transfected with methylated oligonucleotides was significantly higher than that of control cells.
CONCLUSION: Methylated oligonucleotides that are complementary to the CHFR gene promoter can induce CHFR gene promoter methylation, suppress CHFR mRNA expression, and promote cell proliferation in human colon cancer cell line SW480.
Collapse
|
36
|
Liu H, Galka M, Iberg A, Wang Z, Li L, Voss C, Jiang X, Lajoie G, Huang Z, Bedford MT, Li SSC. Systematic identification of methyllysine-driven interactions for histone and nonhistone targets. J Proteome Res 2010; 9:5827-36. [PMID: 20836566 DOI: 10.1021/pr100597b] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
An important issue in epigenetic research is to understand how the numerous methylation marks associated with histone and certain nonhistone proteins are recognized and interpreted by the hundreds of chromatin-binding modules (CBMs) in a cell to control chromatin state, gene expression, and other cellular functions. We have assembled a peptide chip that represents known and putative lysine methylation marks on histones and p53 and probed the chip for binding to a group of CBMs to obtain a comprehensive interaction network mediated by lysine methylation. Interactions revealed by the peptide array screening were validated by in-solution binding assays. This study not only recapitulated known interactions but also uncovered new ones. A novel heterochromatin protein 1 beta (HP1β) chromodomain-binding site on histone H3, H3K23me, was discovered from the peptide array screen and subsequently verified by mass spectrometry. Data from peptide pull-down and colocalization in cells suggest that, besides the H3K9me mark, H3K23me may play a role in facilitating the recruitment of HP1β to the heterochromatin. Extending the peptide array and mass spectrometric approach presented here to more histone marks and CBMs would eventually afford a comprehensive specificity and interaction map to aid epigenetic studies.
Collapse
Affiliation(s)
- Huadong Liu
- Department of Biochemistry, The University of Western Ontario, London, Ontario, N6A 5C1, Canada
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Small molecule modulators of histone acetylation and methylation: a disease perspective. BIOCHIMICA ET BIOPHYSICA ACTA-GENE REGULATORY MECHANISMS 2010; 1799:810-28. [PMID: 20888936 DOI: 10.1016/j.bbagrm.2010.09.005] [Citation(s) in RCA: 42] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/18/2010] [Revised: 09/18/2010] [Accepted: 09/24/2010] [Indexed: 11/22/2022]
Abstract
Chromatin modifications have gained immense significance in the past few decades as key regulators of gene expression. The enzymes responsible for these modifications along with the other non-histone proteins, remodeling factors and small RNAs modulate the chromatin dynamicity, which in turn directs the chromatin function. A concerted action of different modifying enzymes catalyzes these modifications, which are read by effector modules and converted to functional outcomes by various protein complexes. Several small molecules in the physiological system such as acetyl CoA, NAD(+), and ATP are actively involved in regulating these functional outcomes. Recent understanding in the field of epigenetics indicate the possibility of the existence of a network, 'the epigenetic language' involving cross talk among different modifications that could regulate cellular processes like transcription, replication and repair. Hence, these modifications are essential for the cellular homeostasis, and any alteration in this balance leads to a pathophysiological condition or disease manifestation. Therefore, it is becoming more evident that modulators of these modifying enzymes could be an attractive therapeutic strategy, popularly referred to as 'Epigenetic therapy.' Although this field is currently monopolized by DNA methylation and histone deacetylase inhibitors, this review highlights the modulators of the other modifications namely histone acetylation, lysine methylation and arginine methylation and argues in favor of their therapeutic potential.
Collapse
|